Summit Securities Group’s Bristol-Myers Squibb BMY Stock Holding History

Summit Securities Group’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$190K	Sell	3,134 -82,290	-96%	-$4.8M	0.02%	231
2025 Q4	$4.61M	Buy	85,424 +76,816	+892%	+$3.7M	0.6%	37
2025 Q3	$388K	Buy	8,608 +5,138	+148%	+$240K	0.08%	188
2025 Q2	$161K	Sell	3,470 -6,230	-64%	-$306K	0.03%	283
2025 Q1	$592K	Sell	9,700 -42,000	-81%	-$2.45M	0.09%	101
2024 Q4	$2.92M	Buy	51,700 +49,200	+1,968%	+$2.75M	0.6%	37
2024 Q3	$129K	Hold	2,500	–	–	0.03%	175
2024 Q2	$104K	Hold	2,500	–	–	0.02%	211
2024 Q1	$136K	Sell	2,500 -7,400	-75%	-$377K	0.02%	176
2023 Q4	$508K	Sell	9,900 -400	-4%	-$21K	0.05%	188
2023 Q3	$598K	Sell	10,300 -6,395	-38%	-$392K	0.06%	115
2023 Q2	$1.07M	Buy	16,695 +8,925	+115%	+$598K	0.14%	96
2023 Q1	$539K	Sell	7,770 -43,459	-85%	-$3.07M	0.04%	135
2022 Q4	$3.69M	Buy	51,229 +4,940	+11%	+$372K	0.14%	94
2022 Q3	$3.29M	Sell	46,289 -27,163	-37%	-$1.97M	0.25%	66
2022 Q2	$5.66M	Sell	73,452 -4,441	-6%	-$338K	0.7%	27
2022 Q1	$5.69M	Buy	77,893 +38,160	+96%	+$2.56M	0.64%	29
2021 Q4	$2.48M	Buy	39,733 +4,933	+14%	+$289K	0.12%	141
2021 Q3	$2.06M	Sell	34,800 -39,436	-53%	-$2.6M	0.16%	151
2021 Q2	$4.96M	Buy	74,236 +4,736	+7%	+$309K	0.41%	51
2021 Q1	$4.39M	Sell	69,500 -50,300	-42%	-$3.13M	0.48%	39
2020 Q4	$7.43M	Buy	119,800 +5,652	+5%	+$348K	0.63%	31
2020 Q3	$6.88M	Sell	114,148 -22,398	-16%	-$1.35M	0.72%	30
2020 Q2	$8.03M	Sell	136,546 -76,628	-36%	-$4.58M	1%	20
2020 Q1	$11.9M	Sell	213,174 -139,301	-40%	-$8.51M	2.09%	9
2019 Q4	$22.6M	Buy	352,475 +278,433	+376%	+$15.9M	1.71%	9
2019 Q3	$3.75M	Buy	74,042 +44,800	+153%	+$2.11M	0.33%	51
2019 Q2	$1.33M	Buy	+29,242	New	+$1.36M	0.15%	108
2019 Q1	–	Sell	-27,400	Closed	-$1.36M	–	207
2018 Q4	$1.42M	Buy	+27,400	New	+$1.47M	0.12%	104
2018 Q2	–	Sell	-3,800	Closed	-$240K	–	223
2018 Q1	$240K	Sell	3,800 -24,200	-86%	-$1.56M	0.06%	127
2017 Q4	$1.72M	Buy	28,000 +16,100	+135%	+$1.01M	0.2%	44
2017 Q3	$759K	Buy	+11,900	New	+$695K	0.13%	80
2017 Q2	–	Sell	-12,632	Closed	-$687K	–	252
2017 Q1	$687K	Buy	12,632 +8,632	+216%	+$473K	0.2%	106
2016 Q4	$234K	Sell	4,000 -7,950	-67%	-$435K	0.05%	235
2016 Q3	$644K	Buy	+11,950	New	+$768K	0.22%	61
2016 Q1	–	Sell	-14,000	Closed	-$963K	–	159
2015 Q4	$963K	Buy	14,000 +11,900	+567%	+$786K	0.31%	52
2015 Q3	$124K	Sell	2,100 -11,100	-84%	-$704K	0.09%	107
2015 Q2	$878K	Buy	13,200 +10,400	+371%	+$685K	0.43%	25
2015 Q1	$181K	Sell	2,800 -40,800	-94%	-$2.55M	0.14%	90
2014 Q4	$2.57M	Buy	43,600 +14,600	+50%	+$823K	0.74%	23
2014 Q3	$1.48M	Buy	29,000 +9,200	+46%	+$460K	0.43%	55
2014 Q2	$960K	Buy	+19,800	New	+$976K	0.33%	53
2014 Q1	–	Sell	-38,600	Closed	-$2.05M	–	414
2013 Q4	$2.05M	Sell	38,600 -4,800	-11%	-$245K	0.36%	47
2013 Q3	$2.01M	Buy	43,400 +26,200	+152%	+$1.15M	0.68%	26
2013 Q2	$769K	Buy	+17,200	New	+$747K	0.37%	52

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Summit Securities Group's BMY Position: Q1 2026 in Review

Summit Securities Group reduced its Bristol-Myers Squibb (BMY) stake by 96% in Q1 2026, selling an estimated $4.8M and leaving 3,134 shares worth $190K. The position accounts for 0.02% of the portfolio, ranked #231.

Summit Securities Group first reported a position in BMY in Q2 2013 and has held it in 45 quarters since. The position peaked at $22.6M in Q4 2019. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Summit Securities Group held 3,134 shares of Bristol-Myers Squibb worth $190K as of Q1 2026.
Summit Securities Group sold 82,290 Bristol-Myers Squibb shares in Q1 2026, an estimated $4.8M.
Bristol-Myers Squibb made up 0.02% of Summit Securities Group's portfolio in Q1 2026, its #231 holding.
Summit Securities Group first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 45 quarters since.
Summit Securities Group's Bristol-Myers Squibb position peaked at $22.6M in Q4 2019.
2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Summit Securities Group's 13F filing for Q1 2026, filed 30 Apr 2026.